Cargando…
EGFR基因少见突变型非小细胞肺癌的临床特征及应用EGFR-TKIs治疗效果评价
BACKGROUND AND OBJECTIVE: Adenocarcinoma is the most common type of lung cancer. It has been clinically evaluated that therapiestargeting against the epidermal growth factor receptor (EGFR) as the clinical standard first-line treatment. The response and outcome of EGFR-tyrosine kinase inhibitors (TK...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533192/ https://www.ncbi.nlm.nih.gov/pubmed/31109439 http://dx.doi.org/10.3779/j.issn.1009-3419.2019.05.06 |